lipoteichoic acid

Lipoteichoic acid, a polymer of the cell wall of gram-positive bacteria, activates the complement system by inducing C3 and inhibiting CD55, and reduces fat deposition via the IGF-1 pathway.

LtaS-IN-1 is an effective inhibitor of Lipoteichoic acid synthesis in multidrug-resistant (MDR) E. faecium and by altering the cell wall morphology. LtaS-IN-1 is against Enterococcus spp 28 strains with varying MIC values ranging from 0.5 μg/mL to 64 μg/mL. LtaS-IN-1 inhibits strain E1630 and E1590 with MIC values of 0.5 μg/mL.

Anti-MRSA agent 25 (Compound 10c) is an antibacterial compound with a minimum inhibitory concentration (MIC) of 0.25 μg/mL against methicillin-resistant Staphylococcus aureus (MRSA). Its antimicrobial activity is achieved by inhibiting biofilm formation, disrupting the cell wall (interacting with peptidoglycan and lipoteichoic acid), acting on the cell membrane (causing depolarization, increasing permeability, and compromising integrity), reducing metabolic activity, interfering with cellular redox homeostasis, and binding to DNA. Anti-MRSA agent 25 holds potential for research in the field of anti-infective therapeutics.

Pagibaximab is a human chimeric monoclonal antibody targeting lipoteichoic acid, a surface fatty acid of Staphylococcus, for preventing Staphylococcus infections.